Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 10;41(5):1132-1146.
doi: 10.1200/JCO.22.02328. Epub 2022 Dec 15.

Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline

Emrullah Yilmaz  1 , Nofisat Ismaila  2 , Julie E Bauman  3 , Raetasha Dabney  4 , Gregory Gan  5 , Richard Jordan  6 , Marnie Kaufman  7 , Kedar Kirtane  8 , Sean Matthew McBride  9 , Matthew O Old  10 , Lisa Rooper  11 , Nabil F Saba  12 , Siddharth Sheth  13 , Rathan M Subramaniam  14   15 , Trisha Michel Wise-Draper  16 , Deborah Wong  17 , Loren K Mell  18
Affiliations
Review

Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline

Emrullah Yilmaz et al. J Clin Oncol. .

Abstract

Purpose: To provide evidence-based recommendations for practicing physicians and other health care providers on immunotherapy and biomarker testing for head and neck cancers.

Methods: ASCO convened an Expert Panel of medical oncology, surgical oncology, radiation oncology, radiology, pathology, and patient advocacy experts to conduct a literature search, including systematic reviews, meta-analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 2000 through 2022. Outcomes of interest included survival, overall response, and locoregional control. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations.

Results: The literature search identified 28 relevant studies to inform the evidence base for this guideline.

Recommendations: When possible, evidence-based recommendations were developed to address biomarker testing, first-line treatment regimens based on programmed death ligand-1 scores, immunotherapy in platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma, immunotherapy in nasopharyngeal carcinoma, and radiation therapy in combination with immunotherapy for treatment of local recurrence.Additional information is available at www.asco.org/head-neck-cancer-guidelines.

PubMed Disclaimer